ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The advent of tyrosine kinase inhibitors (TKIs) targeting the kinase activity of BCR–ABL1 has transformed CML from a fatal disease to a controllable one for the vast majority of patients2.